{"id":"F2022L00013","name":"Statement of Principles concerning hypothyroidism (Reasonable Hypothesis) (No. 3 of 2022)","slug":"statement-of-principles-concerning-hypothyroidism-reasonable-hypothesis-no-3-of-2022","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":441160,"registerId":"F2022L00013-fast-fetch-1775956533569","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning hypothyroidism (Reasonable Hypothesis) (No. 3 of 2022)","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\nmeta-generator: Aspose.Words for .NET 20.2\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n\n\n \n\nStatement of Principles\n\nconcerning\n\nHYPOTHYROIDISM (Reasonable Hypothesis)\n\n(No. 3 of 2022)\n\nThe Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n \n\nDated 24 December 2021\n\n \n\n \n\n \n\n \n\n \n\n| The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:
|\n| --- |\n|
Professor Terence Campbell AM
Chairperson
|\n\n\n \n\n \n\n\nContents\n\n1 Name\n\n2 Commencement\n\n3 Authority\n\n4 Repeal\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\n \n\n\n\n\n1 Name\n\nThis is the Statement of Principles concerning hypothyroidism (Reasonable Hypothesis) (No. 3 of 2022).\n\n2 Commencement\n\n This instrument commences on 31 January 2022.\n\n3 Authority\n\nThis instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n4 Repeal\n\nThe Statement of Principles concerning hypothyroidism No. 29 of 2013 (Federal Register of Legislation No. F2013L00728) made under subsections 196B(2) and (8) of the VEA is repealed.\n\n5 Application\n\nThis instrument applies to a claim to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n6 Definitions\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n(1) This Statement of Principles is about hypothyroidism and death from hypothyroidism.\n\nMeaning of hypothyroidism\n\n(2) For the purposes of this Statement of Principles, hypothyroidism:\n\n(a) means a functional disorder in which there is deficiency of thyroid hormone that produces clinical symptoms and signs or warrants medical treatment; and\n\n(b) includes:\n\n(i) primary hypothyroidism due to dysfunction of the thyroid gland; and\n\n(ii) central hypothyroidism due to decreased secretion of thyroid hormone from a functionally normal thyroid gland as a result of hypothalamic or pituitary disease; and\n\n(iii) peripheral hypothyroidism due to inactivation of thyroid hormone; and\n\n(c) excludes:\n\n(i) congenital hypothyroidism;\n\n(ii) congenital iodine-deficiency syndrome;\n\n(iii) Hashimoto thyroiditis;\n\n(iv) sick euthyroid syndrome;\n\n(v) subclinical hypothyroidism; and\n\n(vi) transient hypothyroidism during recovery from non-thyroidal illness.\n\nNote 1: Hypothyroidism typically presents with low serum concentrations of the thyroid hormones thyroxine (T4) and/or triiodothyronine (T3), and with an increased concentration of thyroid-stimulating hormone. However, in central hypothyroidism, the thyroid-stimulating hormone concentration may be low to normal.\n\nNote 2: Clinical symptoms and signs of hypothyroidism are nonspecific and typically include fatigue, lethargy, cold intolerance, weight gain, constipation, change in voice and dry skin.\n\nNote 3: In the circumstance where hypothyroidism is a clinical manifestation of Hashimoto thyroiditis, it is covered by the Statements of Principles concerning Hashimoto thyroiditis.\n\nNote 4: Hypothyroidism may be acute or chronic. The acute form may present as myxoedema coma.\n\nNote 5: myxoedema coma is defined in the Schedule 1 - Dictionary.\n\nDeath from hypothyroidism\n\n(3) For the purposes of this Statement of Principles, hypothyroidism, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's hypothyroidism.\n\nNote: terminal event is defined in the Schedule 1 - Dictionary.\n\n8 Basis for determining the factors\n\nThe Repatriation Medical Authority is of the view that there is sound medical‑scientific evidence that indicates that hypothyroidism and death from hypothyroidism can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.\n\nNote: MRCA, relevant service and VEA are defined in the Schedule 1 - Dictionary.\n\n9 Factors that must exist\n\nAt least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting hypothyroidism or death from hypothyroidism with the circumstances of a person's relevant service:\n\n(1) having iodine deficiency within the 6 months before the clinical onset of hypothyroidism;\n\nNote: iodine deficiency is defined in the Schedule 1 - Dictionary.\n\n(2) having iodine excess within the 6 months before the clinical onset of hypothyroidism;\n\nNote 1: Iodine excess may be due to consuming foods, dietary supplements or medications with a high content of iodine.\n\nNote 2: iodine excess is defined in the Schedule 1 - Dictionary.\n\n(3) being administered an iodine-containing radiographic contrast agent within the 6 months before the clinical onset of hypothyroidism;\n\n(4) taking a drug from the specified list of drugs within the 6 months before the clinical onset of hypothyroidism;\n\nNote: specified list of drugs is defined in the Schedule 1 - Dictionary.\n\n(5) taking minocycline for at least 6 months within the 9 months before the clinical onset of hypothyroidism;\n\n(6) taking a drug containing at least 10 milligrams of iodine daily for a continuous period of at least 4 weeks within the 6 months before the clinical onset of hypothyroidism;\n\n(7) taking amiodarone for a continuous period of at least 2 weeks within the 1 year before the clinical onset of hypothyroidism;\n\n(8) being pregnant or within the 12 months postpartum at the time of the clinical onset of hypothyroidism;\n\n(9) having a form of thyroiditis from the specified list of forms of thyroiditis at the time of the clinical onset of hypothyroidism;\n\nNote: specified list of forms of thyroiditis is defined in the Schedule 1 - Dictionary.\n\n(10) undergoing a course of therapeutic radiation for cancer, where the thyroid gland was in the field of radiation, before the clinical onset of hypothyroidism;\n\n(11) having received iodine-131 (radioactive iodine) treatment before the clinical onset of hypothyroidism;\n\n(12) having subtotal or total thyroidectomy, or neck surgery involving the thyroid gland, before the clinical onset of hypothyroidism;\n\n(13) having a disease involving the thyroid gland from the specified list of diseases at the time of the clinical onset of hypothyroidism;\n\nNote: specified list of diseases is defined in the Schedule 1 - Dictionary.\n\n(14) having a primary or secondary malignant neoplasm of the thyroid gland at the time of the clinical onset of hypothyroidism;\n\n(15) having a type 3 deiodinase-overexpressing neoplasm before the clinical onset of hypothyroidism;\n\n(16) having hypopituitarism involving deficiency of thyroid-stimulating hormone at the time of the clinical onset of hypothyroidism;\n\n(17) having chronic kidney disease at the time of the clinical onset of hypothyroidism;\n\nNote: chronic kidney disease is defined in the Schedule 1 - Dictionary.\n\n(18) having hepatitis C virus infection at the time of the clinical onset of hypothyroidism;\n\n(19) being obese for at least 5 years before the clinical onset of hypothyroidism;\n\nNote: being obese is defined in the Schedule 1 - Dictionary.\n\n(20) having posttraumatic stress disorder at the time of the clinical onset of hypothyroidism;\n\n(21) for hypothyroidism first presenting as myxoedema coma only, having an acute precipitating event within the 48 hours before the clinical onset of hypothyroidism;\n\nNote: acute precipitating event and myxoedema coma are defined in the Schedule 1 - Dictionary.\n\n(22) having iodine deficiency within the 6 months before the clinical worsening of hypothyroidism;\n\nNote: iodine deficiency is defined in the Schedule 1 - Dictionary.\n\n(23) having iodine excess within the 6 months before the clinical worsening of hypothyroidism;\n\nNote 1: Iodine excess may be due to consuming foods, dietary supplements or medications with a high content of iodine.\n\nNote 2: iodine excess is defined in the Schedule 1 - Dictionary.\n\n(24) being administered an iodine-containing radiographic contrast agent within the 6 months before the clinical worsening of hypothyroidism;\n\n(25) taking a drug from the specified list of drugs within the 6 months before the clinical worsening of hypothyroidism;\n\nNote: specified list of drugs is defined in the Schedule 1 - Dictionary.\n\n(26) taking minocycline for at least 6 months within the 9 months before the clinical worsening of hypothyroidism;\n\n(27) taking a drug containing at least 10 milligrams of iodine daily for a continuous period of at least 4 weeks within the 6 months before the clinical worsening of hypothyroidism;\n\n(28) taking amiodarone for a continuous period of at least 2 weeks within the 1 year before the clinical worsening of hypothyroidism;\n\n(29) taking a drug that increases the requirement of thyroid hormone replacement therapy at the time of the clinical worsening of hypothyroidism;\n\nNote: Examples of drugs that may increase the requirement for thyroid hormone replacement therapy include 5-fluorouracil, antiretroviral drugs, clofibrate, raloxifene and tamoxifen.\n\n(30) being pregnant or within the 12 months postpartum at the time of the clinical worsening of hypothyroidism;\n\n(31) having a form of thyroiditis from the specified list of forms of thyroiditis at the time of the clinical worsening of hypothyroidism;\n\nNote: specified list of forms of thyroiditis is defined in the Schedule 1 - Dictionary.\n\n(32) undergoing a course of therapeutic radiation for cancer, where the thyroid gland was in the field of radiation, before the clinical worsening of hypothyroidism;\n\n(33) having received iodine-131 (radioactive iodine) treatment before the clinical worsening of hypothyroidism;\n\n(34) having subtotal or total thyroidectomy, or neck surgery involving the thyroid gland, before the clinical worsening of hypothyroidism;\n\n(35) having a disease involving the thyroid gland from the specified list of diseases at the time of the clinical worsening of hypothyroidism;\n\nNote: specified list of diseases is defined in the Schedule 1 - Dictionary.\n\n(36) having a primary or secondary malignant neoplasm of the thyroid gland at the time of the clinical worsening of hypothyroidism;\n\n(37) having a type 3 deiodinase-overexpressing neoplasm before the clinical worsening of hypothyroidism;\n\n(38) having hypopituitarism involving deficiency of thyroid-stimulating hormone at the time of the clinical worsening of hypothyroidism;\n\n(39) having chronic kidney disease at the time of the clinical worsening of hypothyroidism;\n\nNote: chronic kidney disease is defined in the Schedule 1 - Dictionary.\n\n(40) having hepatitis C virus infection at the time of the clinical worsening of hypothyroidism;\n\n(41) being obese for at least 5 years before the clinical worsening of hypothyroidism;\n\nNote: being obese is defined in the Schedule 1 - Dictionary.\n\n(42) having posttraumatic stress disorder at the time of the clinical worsening of hypothyroidism;\n\n(43) for myxoedema coma only, having an acute precipitating event within the 48 hours before that clinical worsening of hypothyroidism;\n\nNote: acute precipitating event and myxoedema coma are defined in the Schedule 1 - Dictionary.\n\n(44) inability to obtain appropriate clinical management for hypothyroidism.\n\n10 Relationship to service\n\n(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n\n(2) The factors set out in subsections 9(22) to 9(44) apply only to material contribution to, or aggravation of, hypothyroidism where the person's hypothyroidism was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nIn this Statement of Principles:\n\n(1) if a factor referred to in section 9 applies in relation to a person; and\n\n(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\n \n\n \n\nSchedule 1 - Dictionary \n\nNote: See Section 6\n\n1 Definitions\n\nIn this instrument:\n\n acute precipitating event means a physical stimulus or event that causes a sudden, intense physical response.\n\nNote: Examples of an acute precipitating event include:\n\n(a) abrupt cessation of thyroxine therapy;\n\n(b) acute illness including cerebrovascular accident, gastrointestinal bleed, myocardial infarction and pulmonary embolism;\n\n(c) acute iodine load including iodine-containing drugs;\n\n(d) drugs including sedatives, opioids, antipsychotics, selective serotonin reuptake inhibitors, phenytoin, beta blockers, diuretics and chemotherapeutic agents;\n\n(e) hypothermia;\n\n(f) infection including pneumonia, urinary tract infections and septicaemia;\n\n(g) physical trauma including burns; and\n\n(h) surgery.\n\n albuminuria means an albumin to creatinine ratio of at least 3 mg/mmol.\n\n being obese means having a Body Mass Index (BMI) of 30 or greater.\n\nNote: BMI is also defined in the Schedule 1 - Dictionary.\n\n BMI means W/H2 where:\n\n(a) W is the person's weight in kilograms; and\n\n(b) H is the person's height in metres.\n\n chronic kidney disease means:\n\n(a) having a glomerular filtration rate of less than 60 mL/min/1.73 m2 for at least 3 months; or\n\n(b) having albuminuria for at least 3 months; or\n\n(c) having kidney damage, as evidenced by renal biopsy, imaging studies, urinary sediment abnormalities or other markers of abnormal renal function; or\n\n(d) having had a kidney transplant.\n\nNote: albuminuria is also defined in the Schedule 1 - Dictionary.\n\n hypothyroidism—see subsection 7(2).\n\n iodine deficiency means:\n\n(a) an average intake of iodine of less than 150 micrograms of iodine per day, or less than 250 micrograms per day for pregnant or lactating women, for a continuous period of at least 30 days; or\n\n(b) having a urinary iodine concentration of less than 100 micrograms per litre, or less than 150 micrograms per litre for pregnant women.\n\n iodine excess means:\n\n(a) an average intake of more than 1,100 micrograms of iodine per day for adults, or more than 900 micrograms per day for those aged 18 years and under, for a continuous period of at least 3 months; or\n\n(b) having a urinary iodine concentration of greater than 300 micrograms per litre, or greater than 500 micrograms per litre for pregnant women.\n\n MRCA means the Military Rehabilitation and Compensation Act 2004.\n\n myxoedema coma means a constellation of severe and life-threatening symptoms of rapid onset in a patient with biochemical evidence of decreased thyroxine level. Characteristic symptoms and signs are decreased mental status and hypothermia, and hypotension, bradycardia, hyponatremia, hypoglycaemia and hypoventilation are typically present.\n\nNote 1: Myxoedema coma is also known as decompensated hypothyroidism.\n\nNote 2: Myxoedema coma may be the first presentation of undiagnosed hypothyroidism, or may complicate existing hypothyroidism.\n\n relevant service means:\n\n(a) operational service under the VEA;\n\n(b) peacekeeping service under the VEA;\n\n(c) hazardous service under the VEA;\n\n(d) British nuclear test defence service under the VEA;\n\n(e) warlike service under the MRCA; or\n\n(f) non-warlike service under the MRCA.\n\nNote: MRCA and VEA are also defined in the Schedule 1 - Dictionary.\n\n specified list of diseases means:\n\n(a) amyloidosis;\n\n(b) hereditary haemochromatosis;\n\n(c) Langerhan cell histiocytosis;\n\n(d) Pneumocystis jirovecii infection;\n\n(e) sarcoidosis;\n\n(f) systemic lupus erythematosus;\n\n(g) systemic sclerosis (scleroderma); or\n\n(h) tuberculosis.\n\n specified list of drugs means:\n\n(a) alemtuzumab;\n\n(b) alitretinoin;\n\n(c) aminoglutethimide;\n\n(d) antithyroid drugs;\n\n(e) antituberculous drugs for multidrug resistant tuberculosis;\n\n(f) bexarotene;\n\n(g) carbamazepine;\n\n(h) ethionamide;\n\n(i) immune checkpoint inhibitors;\n\n(j) interferon alpha;\n\n(k) interleukin-2;\n\n(l) lenalidomide;\n\n(m) lithium carbonate;\n\n(n) mitotane;\n\n(o) oxcarbazepine;\n\n(p) phenobarbital;\n\n(q) phenytoin;\n\n(r) pomalidomide;\n\n(s) quetiapine;\n\n(t) ritonavir;\n\n(u) thalidomide;\n\n(v) tyrosine kinase inhibitors; or\n\n(w) valproic acid.\n\n specified list of forms of thyroiditis means:\n\n(a) drug-induced thyroiditis;\n\n(b) infectious thyroiditis;\n\n(c) Riedel thyroiditis;\n\n(d) silent thyroiditis, including postpartum thyroiditis; or\n\n(e) subacute thyroiditis.\n\nNote 1: Infectious thyroiditis may be due to a mycobacterial or fungal infection of the thyroid gland. Organisms that can cause infectious thyroiditis include Mycobacterium tuberculosis, Pneumocystis jirovecii and fungi belonging to the species Aspergillus, Candida or Coccidioides.\n\nNote 2: Subacute thyroiditis is also known as de Quervain thyroiditis, granulomatous thyroiditis, giant cell thyroiditis or non-suppurative thyroiditis.\n\n terminal event means the proximate or ultimate cause of death and includes the following:\n\n(a) pneumonia;\n\n(b) respiratory failure;\n\n(c) cardiac arrest;\n\n(d) circulatory failure; or\n\n(e) cessation of brain function.\n\n VEA means the Veterans' Entitlements Act 1986.\n\n \n\n \n","sortOrder":0}],"analysis":{"flash_summary":{"complexity_score":7,"scope_assessment":{"changed":true,"description":"This instrument expands and refines the operational scope of the SOP compared with the prior 2013 Statement (which is expressly repealed at s.4). Changes that widen or refine scope include: (a) updating and listing a broader set of specified drugs (including newer agents such as immune checkpoint inhibitors and tyrosine kinase inhibitors) and forms of thyroiditis (Schedule 1: specified list of drugs; specified list of forms of thyroiditis); (b) adding 'inability to obtain appropriate clinical management' as an enumerated factor for clinical worsening (s.9(44)); (c) distinguishing more clearly between factors that trigger a \"reasonable hypothesis\" for clinical onset versus for clinical worsening, and applying a specific limitation where hypothyroidism pre‑dates service (s.9; s.10(2)); and (d) providing more detailed quantitative thresholds for iodine deficiency and excess and other clinical markers (Schedule 1). These changes broaden the set of factual circumstances that, if established and related to service, can support claims and impose more precise evidentiary requirements (timing/duration/biomarkers) on claimants and decision‑makers."},"complexity_factors":["44 enumerated factors in section 9, many replicated for both 'clinical onset' and 'clinical worsening' creating parallel conditional branches","Approximately 16 distinct defined terms in Schedule 1 (e.g. iodine deficiency/excess, myxoedema coma, chronic kidney disease, specified lists of drugs/diseases/forms of thyroiditis, BMI)","Multiple and varied temporal windows and duration requirements (e.g. within 6 months, 9 months, 1 year, 48 hours, continuous periods of 4 weeks, 3 months, 5 years)","Cross‑references to other Statements of Principles where factors refer to conditions covered elsewhere (s.11), increasing inter‑instrument dependence","Exclusion list for hypothyroidism that routes some conditions to other SOPs (s.7(2)(c)), requiring assessors to consult multiple instruments","Conditional limitation in s.10(2) restricting subsections 9(22)–9(44) to pre‑existing hypothyroidism that was not 'arising out of' service, adding a second‑order condition to apply those factors","Technical biomarker thresholds (urinary iodine, GFR, albuminuria) requiring clinical data rather than simple records","Repeal and replacement of a prior SOP (s.4) — requires comparison with previous instrument when assessing scope change or claims in transition"],"plain_english_summary":"**What this instrument does (mechanically)\n\n- Replaces the earlier 2013 Statement of Principles on hypothyroidism and sets a new Statement of Principles (SOP) under the Veterans' Entitlements Act (s.3, s.4). It commences 31 January 2022 (s.2). The Repatriation Medical Authority (RMA) made it under the VEA (s.3).\n\n- Establishes what medical findings and circumstances (\"factors\") are sufficient to raise a \"reasonable hypothesis\" that a person's hypothyroidism (or death from it) is related to their relevant service for the purposes of claims under the VEA or the Military Rehabilitation and Compensation Act (MRCA) (s.5, s.7, s.9). If at least one listed factor is present and is related to the person's relevant service, a reasonable hypothesis is said to be raised (s.9, s.10(1)).\n\n- Lists 44 discrete factors (and many sub-categories) that can connect hypothyroidism to service. These include recent iodine deficiency or excess, exposure to iodine-containing contrast agents, specified drugs or drug‑classes, past thyroid or neck surgery, thyroid radiation or radioactive iodine treatment, certain systemic diseases, pregnancy/postpartum status, obesity (with a specified BMI threshold and duration), chronic kidney disease, hepatitis C, PTSD, and inability to obtain appropriate clinical management, among others (s.9). Many factors have specified time windows before clinical onset or before clinical worsening (for example, \"within 6 months\", \"within 1 year\", \"for at least 5 years\", or \"within 48 hours\" for precipitating events) (s.9).\n\n- Defines hypothyroidism (what is covered and what is excluded) and several technical terms (Schedule 1). It specifically excludes congenital hypothyroidism, Hashimoto thyroiditis (except where that condition itself is covered by the Hashimoto SOP), subclinical hypothyroidism and certain transient forms (s.7(2)(c)).\n\n- Clarifies that some listed factors refer to conditions for which there is a separate SOP; where that is so, the other SOP applies as in force (s.11).\n\n\nWho is affected\n\n- Veterans, members of peacekeeping forces and members of the Australian Defence Force (ADF) whose claims fall under the VEA or the MRCA (s.5, Schedule - definitions of relevant service).\n\n- Decision‑makers within the Department of Veterans' Affairs (DVA) and tribunals who assess whether a condition is service‑related; clinicians who supply medical evidence for claims; and claimants who must produce evidence to satisfy the timing and diagnostic requirements set out in the SOP.\n\n\nWhy it matters (official rationale and how that plays out mechanically)\n\n- The RMA states there is sound medical‑scientific evidence that hypothyroidism and death from it can be related to relevant service (s.8). Mechanically, the SOP converts that medical‑scientific view into a fixed list of factual circumstances that, if established and linked to service, satisfy the statutory \"reasonable hypothesis\" threshold in veteran claims.\n\n- Purpose‑claim test: The SOP aims to give a clear, administrable checklist that lowers uncertainty in claims by specifying what circumstances are sufficient to raise a reasonable hypothesis (s.9, s.11). The effect is to standardise claim assessment by reference to enumerated factors and defined timeframes.\n\n\nPractical effects, incentives and trade‑offs (concrete mechanisms)\n\n- Who pays: If a claimant satisfies the \"reasonable hypothesis\" using an enumerated factor that is related to relevant service, administrative decisions may find the condition service‑related, which can lead to entitlements under the VEA or MRCA. That produces fiscal cost to the Commonwealth through the DVA compensation/medical system (s.5, s.9, s.10).\n\n- Evidence burden on claimants: Many factors require precise timing or durations (for example, iodine exposure within 6 months, amiodarone for at least 2 weeks within the previous year, obesity for at least 5 years). Claimants must supply medical records, prescriptions, imaging, laboratory results (urinary iodine, thyroid hormones), or contemporaneous notes to meet those conditions (s.9, Schedule 1 definitions).\n\n- Administrative and clinical discretion: The SOP reduces some clinical judgment by prescribing required factors and windows, but decision‑makers still must determine whether the factor is \"related to the relevant service\" (s.10(1)). The SOP also defers to other SOPs where a listed factor is itself covered by another Statement (s.11), which can introduce cross‑instrument complexity.\n\n- Interaction with medical practice and private sector actors: The SOP does not regulate prescribing or private medical practice directly. However, listing specific drugs and treatments (Schedule 1: specified list of drugs; items such as immune checkpoint inhibitors, lithium, amiodarone, radioactive iodine, and therapeutic radiation) as possible causal factors may change the evidentiary scrutiny around those treatments in claim contexts and could increase demand for retrospective medical documentation from private clinicians and hospitals.\n\n- Potential substitution effects: Because the SOP distinguishes between \"onset\" and \"clinical worsening\" and allows different sets of factors to apply in each situation (s.9; s.10(2)), claimants may frame medical histories to fit the relevant factor and time window. That is an evidential effect rather than a legal change in entitlement standards.\n\n- Concentrated benefits/diffuse costs (mechanism): The benefits of successful claims are concentrated to individual claimants (veterans/serving members). The fiscal cost of successful claims is spread across the Commonwealth budget. The instrument itself provides the mechanism for channeling these benefits (s.9, s.10).\n\n\nImplementation risks and compliance burden\n\n- Diagnostic ambiguity: Hypothyroidism has non‑specific symptoms and overlapping causes. The SOP both narrows (by excluding conditions such as Hashimoto thyroiditis where a separate SOP applies) and widens (by enumerating many possible precipitating factors) potential causal attributions (s.7(2), s.11).\n\n- Evidence availability: Several factors require laboratory or longitudinal data (urinary iodine concentrations, duration of obesity, drug exposure windows, history of thyroid surgery or radiation). Gaps in medical records will increase processing time and dispute risk.\n\n- Cross‑reference complexity: Where a factor refers to a condition already covered by another SOP, decision‑makers must apply that other SOP as amended over time (s.11). This creates some administrative complexity and potential for inconsistent outcomes if SOPs are not coordinated.\n\n\nConcrete examples of how the SOP operates\n\n- If a veteran was given an iodine‑containing contrast agent 3 months before developing clinically significant hypothyroidism, that single factor (contrast within 6 months) can raise a reasonable hypothesis linking the condition to service — provided the exposure is related to the veteran's relevant service (s.9(3), s.10(1)).\n\n- If a veteran had hypothyroidism before service and it worsened during service, subsections s.9(22)–s.9(44) list factors that can support a finding of material contribution or aggravation; but s.10(2) limits those factors to situations where the condition existed before or during service (but didn’t arise out of service).\n\n\nKey defined thresholds and exclusions (technical anchors)\n\n- Iodine deficiency: <150 µg/day (or <250 µg/day in pregnancy) for 30+ days, or urinary iodine <100 µg/L (<150 µg/L in pregnancy) (Schedule 1).\n\n- Iodine excess: >1,100 µg/day for adults sustained 3+ months, or urinary iodine >300 µg/L (>500 µg/L in pregnancy) (Schedule 1).\n\n- Obesity: BMI ≥30, and the SOP requires obesity for at least 5 years for that factor to apply (Schedule 1; s.9(19), s.9(41)).\n\n- Exclusions: congenital hypothyroidism; congenital iodine‑deficiency syndrome; Hashimoto thyroiditis (covered elsewhere); sick euthyroid syndrome; subclinical hypothyroidism; transient hypothyroidism during recovery from non‑thyroidal illness (s.7(2)(c)).\n\n\nBottom line (mechanical summary)\n\nThis SOP converts current medical evidence into a checklist of defined factors and timeframes that, if established and linked to a person’s relevant service, are sufficient to raise a reasonable hypothesis that hypothyroidism (or death from it) is related to service. It defines precise diagnostic and exposure thresholds, enumerates causal agents and conditions, excludes certain thyroid disorders, and requires relationship to relevant service for the factors to operate (s.7–s.11)."},"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"},"kimi_summary":{"content_quality":"ok","complexity_score":5,"scope_assessment":{"changed":false,"description":"This instrument maintains the established scope of Repatriation Medical Authority Statements of Principles. It replaces the 2013 version (No. 29 of 2013) with updated medical factors but does not expand beyond the traditional purpose of establishing service connection criteria for a specific condition. The structure—covering onset and aggravation with defined factors and a dictionary—follows the standard template for these instruments."},"complexity_factors":["44 distinct factors with specific temporal requirements (ranging from 48 hours to 5+ years before onset/worsening)","21 defined terms in Schedule 1, including nested definitions (e.g., 'chronic kidney disease' relies on 'albuminuria', which has its own definition)","Three separate 'specified lists' containing multiple items: drugs (23 items), diseases (8 items), and forms of thyroiditis (5 items)","Dual structure covering both 'clinical onset' (factors 1-21) and 'clinical worsening' (factors 22-44) with near-mirror logic but critical differences","Specific numerical thresholds throughout (e.g., BMI ≥30, iodine intake >1,100 mcg/day, urinary concentration cutoffs, time periods in weeks/months/years)","Cross-reference mechanism in section 11 allowing other Statements of Principles to be incorporated by reference","Conditional logic in factor 21 and 43 restricting certain factors to 'myxoedema coma only'","Exclusion list in section 7(2)(c) with 6 specific carve-outs from the definition"],"plain_english_summary":"This instrument sets medical criteria for when hypothyroidism can be presumed to be connected to Australian Defence service, replacing the 2013 guidance with updated evidence. It lists 44 medical factors—any one can support a reasonable hypothesis of service connection—and covers new or worsened hypothyroidism for veterans and current/former ADF members making claims under the VEA 1986 or MRCA 2004 across operational, peacekeeping, hazardous, nuclear, warlike and non‑warlike service.\n\nIt excludes congenital hypothyroidism, Hashimoto’s, subclinical cases and transient thyroid dysfunction."}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-hypothyroidism-reasonable-hypothesis-no-3-of-2022","history":"/api/acts/statement-of-principles-concerning-hypothyroidism-reasonable-hypothesis-no-3-of-2022/history","analysis":"/api/acts/statement-of-principles-concerning-hypothyroidism-reasonable-hypothesis-no-3-of-2022/analysis","conflicts":"/api/acts/statement-of-principles-concerning-hypothyroidism-reasonable-hypothesis-no-3-of-2022/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-hypothyroidism-reasonable-hypothesis-no-3-of-2022/important-cases","documents":"/api/acts/statement-of-principles-concerning-hypothyroidism-reasonable-hypothesis-no-3-of-2022/documents"}}